Tomasz Kostrzewski, Paloma Maraver, Larissa Ouro‐Gnao, Ana Levi, Sophie Snow, Alina Miedzik, Krista Rombouts, David Hughes – 13 November 2019 – Nonalcoholic steatohepatitis (NASH) is the most severe form of nonalcoholic fatty liver disease (NAFLD), which to date has no approved drug treatments. There is an urgent need for better understanding of the genetic and molecular pathways that underlie NAFLD/NASH, and currently available preclinical models, be they in vivo or in vitro, do not fully represent key aspects of the human disease state.

Josh Levitsky, Bryna E. Burrell, Sai Kanaparthi, Laurence A. Turka, Sunil Kurian, Alberto Sanchez‐Fueyo, Juan J. Lozano, Anthony Demetris, Andrew Lesniak, Allan D. Kirk, Linda Stempora, Guang‐Yu Yang, James M. Mathew – 13 November 2019

Review a condensed summary of the clinical research highlights from The Liver Meeting.

Review key highlights from all the exciting clinical research presented at The Liver Meeting® 2019.

At the 2019 Leon Schiff State-of-the-Art Lecture, our selected speaker will provide a thorough overview of the advances in knowledge of the pathogenesis of hepatocellular carcinoma (HCC). The lecture will explore current data on evidence-based treatment of this disease, including novel molecular therapies and advances in precision oncology.

Digest a debrief of the newest data on the treatment of viral hepatitis presented at The Liver Meeting.

Harriet Gaskell, Xiaodong Ge, Romain Desert, Sukanta Das, Hui Han, Daniel Lantvit, Grace Guzman, Natalia Nieto – 12 November 2019 – Nonalcoholic steatohepatitis (NASH) is a metabolic disorder in which poor nutrition and the gut‐to‐liver interaction play a major role. We previously established that hepatic high mobility group box‐1 (HMGB1) is involved in chronic liver disease. HMGB1 increases in patients with NASH and it is expressed in intestinal epithelial cells (IEC); yet, the role of intestinal HMGB1 in the pathogenesis of NASH has not been investigated.

Kerstin Schneeberger, Natalia Sánchez‐Romero, Shicheng Ye, Frank G. Steenbeek, Loes A. Oosterhoff, Iris Pla Palacin, Chen Chen, Monique E. Wolferen, Gilles Tienderen, Ruby Lieshout, Haaike Colemonts‐Vroninks, Imre Schene, Ruurdtje Hoekstra, Monique M.A. Verstegen, Luc J.W. Laan, Louis C. Penning, Sabine A. Fuchs, Hans Clevers, Joery De Kock, Pedro M. Baptista, Bart Spee – 12 November 2019

Giuseppe Cullaro, Rajani Sharma, Jonel Trebicka, Andrés Cárdenas, Elizabeth C. Verna – 12 November 2019 – Acute‐on‐chronic liver failure (ACLF) is a feared complication that can develop at any stage of chronic liver disease. The incidence of ACLF is increasing, leading to a significant burden to both the affected individual and health care systems. To date, our understanding of ACLF suggests that it may be initiated by precipitants such as systemic infection, alcohol use, or viral hepatitis.

Po‐Hsun Huang, Chien‐Chang Liao, Meng‐Hsiang Chen, Tung‐Liang Huang, Chao‐Long Chen, Hsin‐You Ou, Yu‐Fan Cheng – 12 November 2019 – Image evaluation of the vascular architecture is essential before living donor liver transplantation (LDLT). However, the use of contrast‐enhanced study in recipients with impaired renal function is limited due to the risk of acute kidney injury and nephrogenic systemic fibrosis. Therefore, a contrast medium–free method is both valuable and necessary for preoperative vascular evaluation.